MedTrace Logo

Human Cerebral Blood Flow and Serotonin

NCT05957094 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-07-24

No results posted yet for this study

Summary

Breathing, blood pressure, and blood flow into the brain are controlled - in part - by small areas in the brainstem; the central chemoreceptors. The mechanisms involved in the transmission of signals through the brainstem and also in controlling brain blood flow past the brainstem both use a molecule called serotonin. Citalopram is a "selective serotonin reuptake inhibitor" (or SSRI) which means it allows serotonin to be released in the brain but stops it from being reabsorbed. SSRIs are often used as antidepressants. This study aims to investigate the influence of an SSRI on the control of brain blood flow.

Conditions

Interventions

DRUG

Pharmacological agent: Citalopram

Participants will be given 40 mg in capsule form, which is a normal clinical dose.

OTHER

Placebo

Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Philip Ainslie, PhD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05957094 on ClinicalTrials.gov